Skip to main content
. Author manuscript; available in PMC: 2020 Mar 30.
Published in final edited form as: Biomed Pharmacother. 2019 Aug 7;118:109323. doi: 10.1016/j.biopha.2019.109323

Fig. 6.

Fig. 6.

Biodistribution profile of 99mTc-SpHL (A) and 99mTc-SpHL-Fol (B) after intravenous administration in 4T1 breast tumor-bearing female BALB/c mice at 4 h and 24 h. (C) Tumor-to-muscle ratio for 99mTc-SpHL and 99mTc-SpHL-Fol. Data are expressed by the mean ± standard deviation of the mean (n = 7). Tumor-to-muscle data were analyzed by one-way ANOVA analysis of variance followed by Tukey’s post-test. aRepresents statistical differences (P < 0.05) between 4 h and 24 h for 99mTc-SpHL or 99mTc-SpHL-Fol treatments. bRepresents statistical differences (P < 0.05) between 99mTc-SpHL and 99mTc-SpHL-Fol at 4 h treatments.